Zhangjiang Biopharma Innovation Continues to Break New Ground with Enhanced Capabilities and Strategic Collaborations

Harbour BioMed and Otsuka Pharmaceutical Co., Ltd. (hereinafter referred to as "Otsuka Pharmaceutical") have reached a global strategic cooperation. Both parties will jointly promote the development of BCMAxCD3 bispecific T-cell engagers for the treatment of autoimmune diseases.

According to the terms of the agreement, Otsuka Pharmaceutical will obtain an exclusive license to develop, manufacture, and commercialize HBM7020 (a BCMAxCD3 bispecific T-cell engager) globally, excluding mainland China, Hong Kong, Macao, and Taiwan. Harbour BioMed will receive a total of US$47 million in upfront and near-term milestone payments.

In addition, upon reaching specific R&D and commercial milestones, Harbour BioMed is entitled to receive up to $623 million in additional payments as well as tiered royalties based on future net product sales. Building on this strategic collaboration, the two parties will explore further opportunities for cooperation in the T-cell engager field.

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, stated that this collaboration highlights the advantages of Harbour BioMed's proprietary technology platforms: "These platforms enable us to rapidly develop fully human bispecific antibodies with optimized safety and efficacy profiles. With our unique technological strengths, we are well-positioned to advance the research and development of next-generation biologics, ultimately benefiting patients worldwide."

It is reported that HBM7020 is a BCMAxCD3 bispecific antibody developed based on Harbour BioMed's fully human HBICE® bispecific antibody technology and Harbour Mice® platform. As a global biopharmaceutical company focusing on the research and development of innovative drugs in the field of immunological diseases and oncology, Harbour BioMed is rapidly expanding its innovative drug R&D pipeline through self-developed, jointly developed, and diversified international cooperation models.

It is understood thatZhangjiang Pharm Valley Platform and Shanghai Weirui Technology Co., Ltd. (hereinafter referred to as "Weirui Technology") have reached a strategic cooperation to jointly build the Zhangjiang Pharm Valley Platform-Weirui Technology Product Application Center (hereinafter referred to as the "Application Center"). Relying on the technical service system of the Zhangjiang Pharm Valley Platform and the cutting-edge innovative technology products independently developed by Weirui Technology, the Application Center will push the conventional flow cytometry detection service capability to the nanoscale.

At the experimental site on the 4th floor of Building 781, Cai Lun Road, Zhangjiang Pharm Valley Platform, the Application Center is equipped with a nano-flow cytometer and a nano-flow sorter. Based on particle size, it performs precise sorting and conducts physical property and biological activity detection analysis of cells through fluorescence labeling. Currently, the Application Center has fully launched professional technical services for nano-flow analysis and sorting, capable of accurately analyzing small-particle substances such as exosome microvesicles, bacteria, viruses, and nanomaterials. This opens up entirely new possibilities for nanoscale scientific research and greatly expands the boundaries of scientific detection.

In recent years, Zhangjiang Pharma Valley has actively built public service platforms by integrating industry advantage resources, helping biopharmaceutical companies make breakthroughs in key areas and core technologies, and promoting the application of scientific and technological achievements. For example, it has builtZhangjiang Synthetic Biology Public Platform, Biopharmaceutical Transformation Platform, Zhangjiang Medical Point, Shanghai In Vitro Diagnostics Standardization and Harmonization Center, Shanghai Jiaotong University Zhangjiang Public Instrument Platform, etc. Nowadays, the Zhangjiang Life Science Industry Public Service Platform covers the complete industrial chain from new drug discovery, drug screening, pharmacological evaluation, clinical research, pilot-scale production, registration certification to mass production and market launch, providing professional services throughout the entire lifecycle of enterprises.

Shanghai NewMed Medical Co., Ltd. (hereinafter referred to as "NewMed") has received approval from the National Medical Products Administration (NMPA) for the market launch of its self-developed next-generation balloon-expandable transcatheter aortic valve system, Prizvalve Pro.

Prizvalve Pro is another significant innovation by NewMed following Prizvalve. Its rapid iteration not only demonstrates the company's strong R&D capabilities in the field of interventional heart valve treatment but also highlights the robust development momentum of innovative medical devices produced in China. This milestone product launch has injected powerful momentum into the field of heart valve disease treatment.

In the multicenter confirmatory clinical study before marketing, Prizvalve Pro demonstrated significant advantages. In actual clinical applications, the product exhibited good safety and effectiveness, with postoperative hemodynamic indicators quickly stabilizing and cardiac function significantly improving, leading to a substantial enhancement in quality of life. Multicenter research data showed that key metrics such as one-year postoperative survival rate and incidence of major complications for patients who underwent surgery using Prizvalve Pro reached internationally excellent levels, strongly proving the product's performance.

The launch of Prizvalve Pro, on the one hand, has broken the long-term monopoly of foreign similar products in the high-end market, achieving the goal of domestic substitution for innovative medical devices. It provides more high-quality and cost-effective options for medical institutions in China, allowing the benefits of innovative medical care to reach a wider population. On the other hand, as an advanced medical device independently developed in China, it demonstrates the country's strength in the field of high-end medical equipment manufacturing. This encourages more domestic companies to increase R&D investment, promotes technological upgrades in related industries, and helps China's medical industry advance to a higher level, contributing to the realization of the Healthy China strategic goals.

NewMed stated that, in the future, it will continue to uphold the mission of "Innovation Benefits Life," constantly optimize product performance, expand the scope of clinical applications, and strengthen cooperation with medical institutions and research academies. It aims to promote the popularization and development of heart valve interventional treatment technology, build a value loop of "technological breakthrough - clinical application - patient benefits," and allow more patients to benefit from the medical advancements brought by technological innovation.